Prognostic Implications of Uterine Cervical Cancer Regression During Chemoradiation Evaluated by the T-Score in the Multicenter EMBRACE I Study.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 06 2022
Historique:
received: 07 12 2021
revised: 31 01 2022
accepted: 03 02 2022
pubmed: 15 2 2022
medline: 18 5 2022
entrez: 14 2 2022
Statut: ppublish

Résumé

A simple scoring system (T-score, TS) for integrating findings from clinical examination and magnetic resonance imaging (MRI) of the primary tumor at diagnosis has shown strong prognostic capability for predicting local control and survival in locally advanced cervical cancer treated with chemoradiation and MRI-guided brachytherapy (BT). The aim was to validate the performance of TS using the multicenter EMBRACE I study and to evaluate the prognostic implications of TS regression obtained during initial chemoradiation. EMBRACE I recruited 1416 patients, of whom 1318 were available for TS. Patients were treated with chemoradiation followed by MRI-guided BT. A ranked ordinal scale of 0 to 3 points was used to assess 8 anatomic locations typical for local invasion of cervical cancer. TS was calculated separately at diagnosis (TS Median TS TS was validated in a multicenter setting and proven to be a strong multidisciplinary platform for integration of clinical findings and imaging with the ability to quantitate local tumor regression and its prognostic implications regarding BT technique, dose-volume histogram parameters, local control, survival, and morbidity.

Identifiants

pubmed: 35157992
pii: S0360-3016(22)00151-1
doi: 10.1016/j.ijrobp.2022.02.005
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

379-389

Subventions

Organisme : Austrian Science Fund FWF
ID : KLI 695
Pays : Austria

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Jacob Christian Lindegaard (JC)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. Electronic address: jacob.lindegaard@auh.rm.dk.

Primoz Petric (P)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Department of Radiation Oncology, University Hospital Zürich, Switzerland.

Maximilian Paul Schmid (MP)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Nicole Nesvacil (N)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Christine Haie-Meder (C)

Department of Radiotherapy, Gustave Roussy, Villejuif, France.

Lars Ulrik Fokdal (LU)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Alina Emiliana Sturdza (AE)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Peter Hoskin (P)

Mount Vernon Cancer Centre, Northwood, United Kingdom.

Umesh Mahantshetty (U)

Homi Bhabha Cancer Hospital & Research Centre, Visakhapatnam, (A Unit of Tata Memorial Centre, Mumbai), India.

Barbara Segedin (B)

Department of Radiotherapy, Institute of Oncology Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Kjersti Bruheim (K)

Department of Oncology, Oslo University Hospital, Oslo, Norway.

Fleur Huang (F)

Department of Oncology, Cross Cancer Institute and University of Alberta, Edmonton, Alberta, Canada.

Bhavana Rai (B)

Department of Radiotherapy and Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Rachel Cooper (R)

St James's University Hospital, Leeds Cancer Centre, Leeds, United Kingdom.

Elzbieta van der Steen-Banasik (E)

Department of Radiotherapy, Radiotherapiegroep Arnhem, Arnhem, The Netherlands.

Erik Van Limbergen (E)

Department of Radiation Oncology, UZ Leuven, Leuven, Belgium.

Bradley Rumwell Pieters (BR)

Department of Radiation Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.

Li-Tee Tan (LT)

Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals, United Kingdom.

Remi A Nout (RA)

Department of Radiation Oncology, Leiden University Medical Center, The Netherlands.

Astrid Agatha Catharina De Leeuw (AAC)

Department of Radiation Oncology, University Medical Centre Utrecht, Utrecht, Netherlands.

Kathrin Kirchheiner (K)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Sofia Spampinato (S)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Ina Jürgenliemk-Schulz (I)

Department of Radiation Oncology, University Medical Centre Utrecht, Utrecht, Netherlands.

Kari Tanderup (K)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Christian Kirisits (C)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Richard Pötter (R)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH